Skip to content

Emotional Intelligence in Schizophrenia and Bipolar-I- Disorder

Emotional Intelligence in Schizophrenia and Bipolar I Disorder: a Comparison Between Patients, Their Siblings, and Healthy Controls

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01998516
Enrollment
350
Registered
2013-11-29
Start date
2013-12-31
Completion date
2017-07-31
Last updated
2017-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar I Disorder, Schizophrenia

Keywords

Emotional Intelligence

Brief summary

Scientific Background Emotional Intelligence (EI) as a part of social cognition is a rather new area of interest which focuses on personality traits and abilities enabling people to cope with both their own feelings as well as those of others. The Mayer-Salovey-Caruso-Emotional-Intelligence-Test (MSCEIT) (1) represents a valid and reliable instrument which exclusively covers the emotional components of social cognition. Recent findings indicate, that social cognitive impairments are useful vulnerability indicators and that EI could be an endophenotype for schizophrenia and bipolar I disorder (BD I). To confirm the endophenotype theory, studies concerning EI in relatives of schizophrenia and bipolar patients are needed. To date, studies on EI in BD patients as well as in first degree relatives of patients with schizophrenia or BD haven't been conducted yet. Accordingly, the current study focuses on the four categories assessed by the MSCEIT and aims to compare the task performance of patients, their first degree relatives and healthy control subjects. We assume that the task performance of relatives lies between that of patients and controls. The confirmation of this assumption would verify the trait marker hypothesis and could be a next step to identify a heritable endophenotype for schizophrenia and BD. Hypotheses Compared to healthy control subjects patients suffering from schizophrenia or BD I show deficits in EI. Siblings of patients with schizophrenia or BD I show deficits in EI and their task performance lies between that of patients and healthy controls. Deficits in EI are more pronounced in schizophrenia patients than in patients with BD I and are more pronounced in siblings of schizophrenia patients than in siblings of patients with BD I. Independently of diagnosis, deficits in EI affect patients' functional and subjective outcomes. Methods Emotional Intelligence will be examined using the MSCEIT in patients with schizophrenia, siblings of schizophrenia patients, patients with BD I, siblings of BD I patients and healthy volunteers matched for age, sex, and educational level. Structured clinical interviews according to DSM-IV (M.I.N.I. + SCID II) will be carried out to assure the diagnosis of schizophrenia or bipolar disorder as well as to detect (comorbid) Axis I and Axis II psychiatric disorders (patients, siblings, control subjects). Functional outcome will be assessed by using the GAF (Global Assessment of Functioning Scale) and the PSP (Personal and Social Performance Scale), subjective quality of life will be examined using the BELP (Berliner Lebensqualiätsprofil). The MWT-B (Multiple choice vocabulary test) will be used to assess premorbid intelligence.

Interventions

None listed

Sponsors

Paracelsus Medical University
CollaboratorOTHER
Austrian Science Fund (FWF)
CollaboratorOTHER
Medical University Innsbruck
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* ICD-10 diagnosis of schizophrenia or BD (verified by Mini International Neuropsychiatric Interview (M.I.N.I.) * Outpatients with stable psychopathology for at least half a year and fixed treatment regimen for at least one month prior to testing * Age: 18-65 years * Native German Speakers * Written informed consent

Exclusion criteria

* Other axis 1 disorder (verified by M.I.N.I.) * History of organic mental disorder * Mental Retardation * Epilepsy * Pregnancy/breast-feeding * Unstable and/or severe organ system diseases, e.g. cardiovascular, endocrine, metabolic

Design outcomes

Primary

MeasureTime frameDescription
Emotional Intelligence24 monthAssessed with the MSCEIT (Mayer-Salovey-Caruso-Emotional-Intelligence-Test

Secondary

MeasureTime frameDescription
Quality of Life24 monthAssessed with the Lancashire Quality of Life Profile

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026